Floatz logo

1-BENZAZOCINE-5-CARBOXAMIDE, 8-(4-(2-BUTOXYETHOXY)PHENYL)-1,2,3,4-TETRAHYDRO-1-(2- METHYLPROPYL)-N-(4-((S)-((1-PROPYL-1H-IMIDAZOL-5-YL)METHYL)SULFINYL)PHENYL)-

Type 2 Diabetes Mellitus

Tobira Therapeutics, Inc.Small moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

142 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

1-BENZAZOCINE-5-CARBOXAMIDE, 8-(4-(2-BUTOXYETHOXY)PHENYL)-1,2,3,4-TETRAHYDRO-1-(2- METHYLPROPYL)-N-(4-((S)-((1-PROPYL-1H-IMIDAZOL-5-YL)METHYL)SULFINYL)PHENYL)- is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
58 / 100
View asset →
prediabetes syndromeDormant
CCC
Indicative ·
52 / 100
View asset →
primary sclerosing cholangitisDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →